Colleagues convinced Penson to give Provenge a try in clinical trials, and he was impressed.

FORBES: A Radical Attack On Prostate Cancer

Patients don't care if a drug meets the original primary endpoint of Dendreon's study, an improvement in X-rays, says Penson.

FORBES: Magazine Article